Start here if you're new
what it is
Edgewise is a biotech company trying to turn muscle-disease drug candidates into real medicines.
how it gets paid
Last year Edgewise Therapeutic made n/a in revenue.
what just happened
Latest reported earnings showed a loss of -$0.39 per share, and this story still depends on pipeline progress, not revenue.
At a glance
B+ balance sheet — decent shape, but not bulletproof
-$1.45 fy2024 eps est
1.35 beta
~$3B market cap
mid cap
xvary composite: 58/100 — below average
What they do
Edgewise is a biotech company trying to turn muscle-disease drug candidates into real medicines.
The edge here is focus, not sales. Edgewise has just 110 employees and two Phase 2 programs aimed at severe muscle diseases, which means your bet is on a small team doing one hard thing well. Orphan disease → very small patient groups → so what: if the data works, you can matter without selling to millions.
How they make money
n/a
annual revenue
The products that matter
muscle-protection drug candidate
sevasemten
key data expected in Q2 2026
This is the lead asset for Becker and Duchenne muscular dystrophy, and Q2 2026 is the date most of the current $3B market value is pointing toward.
lead program
cardiomyopathy program
EDG-7500
Phase 2 · interim safety data reported
This is the second real shot on goal. It has reported interim safety data, but without an efficacy readout yet, it is still more option value than operating business.
pipeline optionality
balance sheet runway
cash position
$530.11M on hand
For a pre-revenue biotech, cash is not a footnote. It is the thing buying time until Q2 2026 and beyond. Without it, the science would not get the chance to prove itself.
funds the wait
Key numbers
-$1.45
2024 EPS est
EPS → profit per share → so what: Edgewise is still losing about $1.45 per share, which tells you this story is still pre-commercial.
5/100
price stability
Price stability → how steady the stock trades → so what: 5 out of 100 says this stock trades on drama, not calm.
0%
debt/capital
Debt to capital → how much the business relies on borrowing → so what: at 0%, lenders are not the immediate risk.
1.35
beta
Beta → how much a stock tends to swing versus the market → so what: at 1.35, you should expect bigger moves than the S&P 500.
Financial health
B+
strength
- balance sheet grade B+ — solid but not elite
- risk rank 2 — safer than 80% of stocks
- price stability 5 / 100
- long-term debt $3M (0% of capital)
B+ — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for EWTX right now.
source: institutional data · return history unavailable
What just happened
reported loss
Latest reported earnings showed a loss of -$0.39 per share, and this story still depends on pipeline progress, not revenue.
Quarterly losses stayed negative through 2024, with EPS at -$0.33, -$0.34, -$0.36, and -$0.42. Full-year EPS improved to -$1.45 from -$1.57 in 2023, but you are still looking at a company without commercial sales in the provided data.
-$0.39
last eps
-$1.45
fy2024 eps est
-$1.56
trailing eps
the number that mattered
The key number is -$1.45 in estimated FY2024 EPS, because it shows losses are still the operating reality even after improving from -$1.57 in FY2023.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
The #1 risk here is sevasemten failing to clear the Q2 2026 hurdle. This is not a diversified biotech revenue base. It is a cash-funded pipeline where one readout carries disproportionate weight.
med
Sevasemten data disappoints
The current setup is simple: $0 revenue today, ~$3B market value today, and a lead program expected to justify that gap. If the Becker or Duchenne path weakens in Q2 2026, the thesis breaks fast.
A bad readout would hit the asset carrying most of the valuation while leaving you with the remaining cash balance, not a proven business.
med
Cash burn outruns the catalyst timeline
$530.11M is a real cushion, but cushions shrink. Delays, broader trial work, or slower progress would make future financing more likely before any approved product exists.
With $0 revenue to offset spending, dilution becomes the default tool if timelines slip far enough.
med
The science works, but the market still gets crowded
Rare-disease drug markets can be large for a small company, but they do not stay empty. Rival approaches in muscular disease can reduce pricing power, partner leverage, and investor patience even if Edgewise posts decent data.
Success is not just clearing the trial. It is clearing the trial with enough differentiation to matter commercially.
The combined risk picture is straightforward: this stock is valued at ~$3B with $0 revenue, so trial execution and cash preservation matter more than any traditional valuation ratio.
source: institutional data · regulatory filings · risk analysis
Pay attention to
catalyst
sevasemten Becker data in Q2 2026
This is the event the stock is really trading on. If the data works, the story extends. If it does not, the valuation has a problem immediately.
pipeline
EDG-7500 moves from safety to efficacy
Interim safety data is not the finish line. You want evidence the program can do more than avoid harm.
cash
quarterly cash burn against the $530.11M base
For a pre-revenue biotech, the runway is a metric, not a footnote. Each quarter tells you how expensive the wait is becoming.
execution
any timeline drift around the Q2 2026 cluster
Two major data moments arriving in one quarter is efficient until one slips. Timeline risk matters because there is no revenue stream to smooth it out.
Analyst rankings
xvary composite
58/100
Below average overall. In human-speak, the cash is respectable but the stock still lives and dies by a small number of pipeline events.
risk rank
2
This rank says the balance sheet is safer than most. It does not mean the trial outcome is safer than most.
beta
1.35
Beta measures market sensitivity. You can translate 1.35 as a stock that usually swings more than the index, then adds biotech headline risk on top.
source: institutional data
Institutional activity
institutional ownership data for EWTX is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$30
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive